FDA Approves Langlara (insulin glargine-aldy), an Interchangeable Biosimilar to Lantus
BLA FilingapprovedLanglaraPositive
AI Analysis
Summary
The FDA approved Langlara (insulin glargine-aldy), an interchangeable biosimilar to Lantus, developed by Lannett Company through its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma.
Outcome Details
FDA approved Langlara (insulin glargine-aldy) as an interchangeable biosimilar to Lantus
Importance:8/10
Sentiment:
0.85
FDA approvalbiosimilarinsulin glargineinterchangeable
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on April 29, 2026 9:05 PM